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Abstract
Background
This study examined the associations of 25-hydroxyvitamin D and specific host genetic vari-
ants that affect vitamin D levels or its effects on immune function, with the risk of TB or mor-
tality in children.
Methods
A case-cohort sample of 466 South African infants enrolled in P1041 trial (NCT00080119)
underwent 25-hydroxyvitamin D testing by chemiluminescent immunoassay. Single nucleo-
tide polymorphisms (SNPs) that alter the effect of vitamin D [e.g. vitamin D receptor (VDR)],
vitamin D levels [e.g. vitamin D binding protein (VDBP)], or toll like receptor (TLR) expression
(SIGIRR including adjacent genes PKP3 and TMEM16J) were identified by real-time PCR.
Outcomes were time to TB, and to the composite of TB or death by 192 weeks of follow-up.
Effect modification between vitamin D status and SNPs for outcomes was assessed.
Findings
Median age at 25-hydroxyvitamin D determination was 8 months; 11% were breastfed, 51%
were HIV-infected and 26% had low 25-hydroxyvitamin D (<32ng/mL). By 192 weeks, 138
PLOSONE | DOI:10.1371/journal.pone.0148649 February 12, 2016 1 / 19
OPEN ACCESS
Citation: Gupta A, Montepiedra G, Gupte A, Zeldow
B, Jubulis J, Detrick B, et al. (2016) Low Vitamin-D
Levels Combined with PKP3-SIGIRR-TMEM16J Host
Variants Is Associated with Tuberculosis and Death in
HIV-Infected and -Exposed Infants. PLoS ONE 11(2):
e0148649. doi:10.1371/journal.pone.0148649
Editor: Sarah L Pett, Faculty of Medicine,
AUSTRALIA
Received: July 21, 2015
Accepted: January 18, 2016
Published: February 12, 2016
Copyright: © 2016 Gupta et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: Overall support for the International
Maternal Pediatric Adolescent AIDS Clinical Trials
Group (IMPAACT) was provided by the National
Institute of Allergy and Infectious Diseases (NIAID) of
the National Institutes of Health (NIH) under Award
Numbers UM1AI068632 (IMPAACT LOC),
UM1AI068616 (IMPAACT SDMC) and UM1AI106716
(IMPAACT LC), with co-funding from the Eunice
Kennedy Shriver National Institute of Child Health
and Human Development (NICHD) and the National
incident TB cases (43 definite/probable, and 95 possible) and 26 deaths occurred. Adjusting
for HIV status and potential confounders, low 25-hydroxyvitamin D was associated with any
TB (adjusted hazard ratio [aHR] 1.76, 95% CI 1.01–3.05; p = 0.046) and any TB or death
(aHR 1.76, 95% CI 1.03–3.00; p = 0.038). Children with low 25-hydroxyvitamin D and
TMEM 16J rs7111432-AA or PKP3 rs10902158-GG were at increased risk for probable/def-
inite TB or death (aHR 8.12 and 4.83, p<0.05) and any TB or death (aHR 4.78 and 3.26,
p<0.005) respectively; SNPs in VDBP, VDR, and vitamin D precursor or hydroxylation
genes were not. There was significant interaction between low 25-hydroxyvitamin D and,
TMEM 16J rs7111432-AA (p = 0.04) and PKP3 rs10902158-GG (p = 0.02) SNPs.
Conclusions
Two novel SNPs, thought to be associated with innate immunity, in combination with low
vitamin D levels were identified as increasing a young child’s risk of developing TB disease
or death. Identifying high-risk children and providing targeted interventions such as vitamin
D supplementation may be beneficial.
Trial Registration
ClinicalTrials.gov NCT00080119
Introduction
Annually, more than 7.6 million children under 15 years of age become infected withMycobac-
terium tuberculosis (Mtb), 650,000 develop tuberculosis disease (TB) and over 74,000 die [1–3].
A substantial number of childhood TB cases and deaths occur in HIV and TB endemic coun-
tries among HIV-infected and -exposed children under 5 years who are at high risk for devel-
oping severe forms of disseminated TB [4]. Prompt and effective diagnosis of TB in children
using currently available diagnostic methods can be challenging [5]. Furthermore, treating
severe forms of TB in children is resource intensive and is often associated with considerable
morbidity and mortality. Thus, strategies aimed at identifying children who are at high risk of
developing TB disease are critical.
In adults, several host factors appear to increase the risk of developing TB or death. For
example, low levels of 25-hydroxyvitamin D (i.e. vitamin D insufficiency and deficiency), are
associated with increased risk of TB infection, TB disease and severity of disease [6–8].
Although the precise mechanisms through which adequate vitamin D protects against TB are
unknown, it is thought to enhance innate immunity by regulating monocyte activation, T-cell
suppression and cytokine synthesis [9]. Furthermore, several host genetic single nucleotide
polymorphisms (SNPs) impacting the vitamin D binding protein (VDBP) as well as the vita-
min D receptor (VDR) have also been linked to increased risk of TB, though with variable qual-
ity of evidence [10–14]. More recently, a significant association between SNPs in the single
immunoglobulin interleukin 1 (IL-1) receptor (SIGIRR, also known as Toll IL-1 receptor 8
[Toll/IL-1R-8, TIR8] region including adjacent SNPs in plakophilin 3 (PKP3) and transmem-
brane 16J (TMEM16J) were associated with susceptibility to TB in Vietnam [15]. This gene
region is associated with innate immune pathways and adaptive immune responses, and acts as
a negative regulator of Toll-like-receptor (TLR) signaling which is important inMtb pathogen-
esis [16, 17]. Interestingly, the antimicrobial activity associated with TLR signaling in
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macrophages was shown to be dependent on the vitamin D pathway [18, 19] and the associa-
tion between low levels of 25-hydroxyvitamin D and TB can be modified by host genotype [8,
20, 21].
Whether the associations between low 25-hydroxyvitamin D, host VDR and other SNPs
associated with TB risk in adults are important to pediatric populations, especially those in
high TB and HIV burden settings, have not been examined. Young children are more likely to
be dependent on innate immunity for control of infections prior to the development of mature
adaptive immunity and are at high risk for developing TB and dying [4].
Thus in the current study, we examined the associations between low 25-hydroxyvitamin D
and host genetic SNPs, including those in the PKP3-SIGIRR-TMEM16J region that are associ-
ated with an increased risk of TB [15], with TB and all-cause mortality among HIV-infected
and –exposed infants in South Africa. We identify a novel interaction between serum vitamin
D levels and genetic variants within the PKP3-SIGIRR-TMEM16J region, which is strongly
associated with TB and death among young children.
Methods
Study design and population
This study had two objectives. First was to measure the prevalence and risk factors of low
25-hydroxyvitamin D in the first year of life. Second was to evaluate the associations between
25-hydroxyvitamin D, specific host SNPs including those in the VDR and VDBP genes as well
as those altering innate immunity in the PKP3-SIGIRR-TMEM16J gene region and, probable
or definite TB in HIV-infected and -exposed infants in a TB-HIV endemic region. Additional
objectives were to evaluate the association between these SNPs and the risk of any TB (possible,
probable, definite TB) as well as composite any TB or death (the primary endpoint in P1041).
All TB outcomes were assessed up to 192 weeks of follow up. We used a case-cohort design to
select 466 infants enrolled in the IMPAACT P1041 trial (Clinical Trials.gov NCT00080119) in
South Africa; the details of this trial are described elsewhere [22]. Briefly, P1041 was a Phase II/
III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of isoni-
azid prophylaxis on TB disease and latentMtb infection free survival in HIV-infected and
HIV-exposed, but uninfected infants up to 192 weeks of follow up. The vast majority of the
1351 infants enrolled between 3 and 4 months of age were from three sites in South Africa
(Johannesburg, Cape Town, and Durban); the one site in Botswana (Gaborone) contributed
<0.5% of participants and was not included in our study. All infants were BCG vaccinated and
had no previous known TB exposure. The DSMB recommend study closure after an interim
analysis showed futility of the isoniazid prophylaxis in both cohorts.
We used a case-cohort design, which allows for both prevalence estimation of the exposures
of interest and multiple outcome assessments without having to test the entire P1041 study
population [23, 24]. Of 1,351 P1041 trial infants, 896 were eligible as they had either archived
serum/plasma (at least 0.125 ml) or peripheral blood mononuclear cells (PBMCs) available;
818 had both. Samples were obtained from two groups: 1) subcohort group: a randomly
selected group of 346 eligible infants with both serum/plasma and PBMC samples; 2) case
group: 120 participants not included in the subcohort who experienced the outcomes of inter-
est (TB or death). The subcohort group included children with TB. As is the convention with
case-cohort studies, the subcohort was used for prevalence estimation and determination of
risk factors for low 25-hydroxyvitamin D. The case group was only included in the assessment
of association between 25-hydroxyvitamin D, host variants and outcomes of interest. For these
analyses, the case group was combined with the subcohort group to form the case-cohort
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sample according to case-cohort design principles (352 for vitamin D analyses and 436 for host
SNPs analyses). (Fig 1)
The analysis reported in this manuscript was conceived after completion of the P1041 trial.
Study participants were enrolled between December 2004 and June 2008, and laboratory analy-
ses on archived samples were performed in 2013. Written informed consent was obtained from
parents or legal guardians on behalf of the children enrolled in our study. Our study was
approved by the Institutional Review Boards and Ethics Committees at Johns Hopkins Univer-
sity, University of California San Diego, Stellenbosch University, University of Witwatersrand,
Soweto, South Africa and the University of KwaZulu Natal, Durban, South Africa.
Laboratory methods
Determination of 25-hydroxyvitamin D concentrations. Total 25-hydroxyvitamin D
concentrations were assessed on archived serum from study entry or a study visit closest to
entry into P1041 using the Diasorin1 chemiluminescent immunoassay. Testing was performed
at Johns Hopkins University, an externally quality-assured laboratory. We defined vitamin D
sufficient as values32 ng/mL, 20 to 31 ng/mL as insufficient, and below 20 ng/mL as deficient
[9, 25–27].
Fig 1. Consort diagram for case-cohort study.
doi:10.1371/journal.pone.0148649.g001
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Genotyping. Using archived PBMCs, we examined SNPs associated with low 25-hydroxy-
vitamin D located within genes that encode VDBP [GC(rs2282679), rs7041, rs4588], 7-dehy-
drocholesterol reductase involved in synthesis of a vitamin D precursor molecule [DHCR7
(rs12785878)] and a hepatic enzyme within the P450 subfamily involved in 25-hydroxylation
of vitamin D [CYP2R1(rs10741657)]. Four VDR SNPs [Fok-l (rs10736810), Bsm-l (rs1544410),
Apa-1 (rs7975232) and Taq-1 (rs731236)] and three SNPs in the PKP3-SIGIRR-TMEM16J
gene region associated with TB susceptibility [PKP3 (rs10902158-A/G), PKP3 (rs7105848-T/
C), and TMEM16J (rs7111432-G/A)][15] were also assessed by real-time PCR assays at the
University of California, San Diego IMPAACT Network Specialty Laboratory.
Statistical methods
Outcome definitions. Low vitamin D was defined as<32 ng/mL. TB was classified as def-
inite, probable or possible based on the 2004 South African National TB Control Program
Guidelines [28]. The diagnostic algorithm is described elsewhere [22]. A definite case wasMtb
cultured from any site. A probable included at least two clinical criteria in the algorithm plus
either positive auramine staining of an induced-sputum or gastric-washing smear or suggestive
histologic findings (e.g. caseating granuloma); or positive auramine staining of a gastric wash-
ing or induced-sputum smear and a chest radiograph suggestive of TB. A possible case was a
clinical algorithm score6 and a radiograph suggestive of TB, or a positive tuberculin skin test
(induration5 mm in horizontal diameter) and a chest radiograph suggestive of TB [22]. Out-
come of death included all-cause mortality and was not restricted to deaths due to TB.
Statistical analysis. Comparisons in baseline characteristics between infants selected for
the subcohort and those not selected among those eligible were assessed using Chi-Square,
Fisher’s exact, and Wilcoxon tests, as appropriate. The prevalence of low 25-hydroxyvitamin D
and SNPs was calculated among the subcohort and 95% confidence intervals were constructed
using Clopper-Pearson exact methodology.[29]
Baseline correlates of low 25-hydroxyvitamin D were assessed using Chi-Square tests. Cox
Proportional Hazards regression models were built to determine the association between low
25-hydroxyvitamin D and outcomes of interest. We also explored Vitamin D level as a contin-
uous variable in models. Formal tests were performed to check the assumption of proportional-
ity of hazards, and no violations were detected. Models were adjusted for the case-cohort
design by using Barlow, Prentice, and Self-Prentice weighting schemes [23, 24]. All models
included low 25-hydroxyvitamin D as the main exposure of interest, adjusting for HIV status,
site, season, sex, WHO weight z-score at baseline, whether or not the child was breastfed, type
of housing, the mother having a previous TB diagnosis, age in months at plasma draw date and
P1041 randomized treatment group of INH or placebo. Models with probable or definite TB as
the outcome of interest did not adjust for whether or not the child was breastfed due to model
stability issues. Association between low 25-hydroxyvitamin D and SNPs among the subcohort
was assessed using Chi-Square tests. Associations between SNPs and the study outcomes
described above were assessed using Cox regression models, adjusting for HIV and vitamin D
status, and included models that additionally adjusted for the other covariates described above
(except for season and age at plasma draw date). Interactions between SNPs and 25-hydroxyvi-
tamin D status were examined and combinations of 25 hydroxyvitamin D status and SNPs
were compared. For all Cox Proportional Hazards regression models involving 25-hydroxyvi-
tamin D status, the plasma draw date (date of earliest available sufficient plasma draw) was the
time at which participants were first considered at-risk. However, for cases when polymor-
phisms were considered without vitamin D status included in the model, participants were
considered at-risk beginning at study entry for P1041. We applied the methodology of Mark
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and Katki [30] to construct Kaplan-Meier (K-M) curves using the full case-cohort. This
method is equivalent to using Self-Prentice weights when the case-cohort sample size is large,
such as in this study. Risk differences were computed as the differences in Kaplan-Meier sur-
vival estimates at end of follow-up period for this analysis, and were not adjusted for
covariates.
The sample size for the sub-cohort corresponds to a sampling fraction of about 30% of the
total cohort size of eligible subjects, since this sampling fraction provides nearly the same
power to detect significant hazard ratios for vitamin D deficiency/insufficiency (assuming vita-
min D deficiency/insufficiency prevalence of 30%) as when the full cohort of eligible subjects
were used in the analysis. Similarly, this sampling fraction provides nearly the same power to
detect significant hazard ratios for genetic variants (assuming genotype prevalence in the range
20%-50%) as when the full cohort were used in the analysis.
Tests resulting in p-value< 0.05 are reported as significant and 0.05< p-value < 0.10 are
reported as marginally significant. Adjustments for multiple testing of exposures of interest
(vitamin D level, genetic variants, and interactions) within each outcome of interest, using Ben-
jamini-Hochberg approach at false discovery rates of FDR = 0.05 and 0.10, are also reported.
Analyses were performed in SAS, version 9.2. K-M curves were constructed using the Nes-
tedCohort package (Version 1.1–2) in R, Version 2.15.1.
Results
Characteristics of study participants
A total of 466 infants comprised the case-cohort sample (346 in the randomly selected subco-
hort and 120 in the case group meeting outcomes of interest but not in the subcohort). There
were 134 TB cases (43 definite or probable and 91 possible cases) and 26 deaths. Of TB cases,
131 were pulmonary and 3 were extrapulmonary. Cause of death included gastroenteritis
(n = 7), pneumonia (n = 6), sepsis (n = 3), other (n = 4) and unknown (n = 6). Among the 215
HIV-infected infants in the full case-cohort, 27 (13%) were never on ARVs prior to or during
the study, 61 (28%) were on ARVs prior to entering the study and 127 (59%) initiated ARVs
during the study, with a median time to ART initiation (from enrollment) of 27 days in the lat-
ter group. 169 (90%) infants received either Stavudine, Lamivudine and Lopinavir/ritonavir or
Lamivudine, Zidovudine and Lopinavir/ritonavir combination therapy. None of the infants
received Efavirenz or Tenofovir based regimes. In the subcohort, 167 (48%) infants were males,
148 (43%) were HIV-infected, 58 (17%) had low birth weight and 39 (11%) were ever breast-
fed (Table 1). Infants included in the subcohort were similar to those not included but eligible,
with the exception of site of enrollment (data not shown). There were significant differences
between children eligible (with relevant samples for the data analysis) and those ineligible with
respect year of enrollment into P1041 (p-value<0.001), HIV status (p-value<0.001), site of
enrollment (p-value<0.001), weight z-score (p-value<0.001), whether there were persons>55
years old in the household or not (p-value = 0.002), housing type (p-value<0.001) and water
access (p-value<0.001), and there was marginally significant difference with respect to whether
the infant was breastfeeding or not at study entry (p-value = 0.09). (S1 Table)
Prevalence and association of low 25-hydroxyvitamin D with TB and
death
The mean age at blood draw for 25-hydroxyvitamin D assessments was 7.59 months. The prev-
alence of low 25-hydroxyvitamin D was 26% (95%CI 21–32), of which 2% were vitamin D defi-
cient and 24% insufficient. (Table 2) Low 25-hydroxyvitamin D status was associated with
Vitamin-D and Host Genetic Variants Are Associated with Childhood TB
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younger age, being female, living in formal houses and birth weight2500 grams (p = 0.048,
0.05, 0.004 and 0.02, respectively). (Table 3)
In analyses only adjusting for HIV status, infants with low 25-hydroxyvitamin D had
approximately a 2-fold greater risk of being diagnosed with probable or definite TB (aHR 1.70,
95%CI 0.64–4.47; p = 0.29, not significant), any TB (aHR 1.99, 95%CI 1.23–3.23; p = 0.005, sig-
nificant), and any TB or death (aHR 2.01; 95%CI 1.31–3.23; p = 0.002, significant) as compared
to their vitamin D sufficient counterparts.(Fig 2A) In multivariable analyses, adjusting for
HIV, site, season, birth weight, breastfeeding, age at plasma draw, house, and INH/placebo
group, low 25-hydroxyvitamin D remained significantly associated with any TB (aHR 1.76,
95%CI 1.01–3.05;p = 0.046) and any TB or death (aHR 1.76, 95%CI 1.03–3.00,p = 0.038).
Table 1. Baseline characteristics of full case-cohort (N = 466).
Characteristic Full Case-cohort
Random sub-cohort Non-subcohort
cases (N = 120**)
Infants chosen for subcohort (N = 346*) Case of subcohort?
No (N = 302) Yes (N = 44)
Infant
Site
Johannesburg 271(78%) 233(77%) 38(86%) 90(75%)
Cape Town 49(14%) 47(16%) 2(5%) 20(17%)
Durban 26(8%) 22(7%) 4(9%) 10(8%)
Male Sex 167(48%) 143(47%) 24(55%) 51(43%)
Mean (sd) age in months 3.26(0.30) 3.26(0.30) 3.30(0.29) 3.28(0.29)
Range of age in months 2.99–3.94 2.99–3.94 2.99–3.91 2.99–3.94
HIV-infected 148(43%) 121(40%) 27(61%) 67(56%)
INH Treatment Group 159(46%) 141(47%) 18(41%) 56(47%)
Birth Weight<2500 gms 58(17%) 50(17%) 8(18%) 19(16%)
Mean (sd) birth weight 2939(562) 2951(565) 2859(544) 2891(482)
Range of birth weight 600–4350 600–4350 1360–3800 1490–4440
Mean (sd)weight z-score -0.77(1.43) -0.73(1.39) -1.10(1.61) -1.21(1.47)
Range of weight z-score -5.84–3.48 -5.84–3.48 -5.19–1.21 -5.41–1.94
Ever breastfed 39(11%) 35(12%) 4(9%) 7(6%)
Maternal and Household
Mother Ever had TB Diagnosis 24(7%) 22(7%) 2(5%) 11(9%)
Housing Type
Formal (brick) house 241(70%) 210(70%) 31(70%) 77(64%)
Informal shack 105(30%) 92(30%) 13(30%) 42(35%)
Water access
Running water in home 124(36%) 108(36%) 16(36%) 39(33%)
Running water on plot 162(47%) 141(47%) 21(48%) 52(43%)
Communal tap 60(17%) 53(17%) 7(16%) 29(24%)
*Of the 346 samples, 333 had evaluable vitamin D or genetic polymorphism data.
** Only the 120 non-cohort cases with evaluable vitamin D or genetic polymorphism data are included. The sub-cohort (n = 346) was the random sample
from the P1041 trial for whom adequate plasma and peripheral blood samples were available. The random sub-cohort had 44 evaluable cases (16
probable/conﬁrmed, 27 possible and 1 death). There were an additional 120 evaluable cases (27 probable/conﬁrmed, 68 possible and 25 deaths) that
contributed to a total evaluable case sample of 164.
doi:10.1371/journal.pone.0148649.t001
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Table 2. Prevalence estimates of Vitamin D and host SNPs of interest in sub-cohort (N = 346***).
Characteristic n(%**)
25 hydroxyvitamin D status
Low* (<32 ng/mL) 70(26.0%)
Deﬁcient (<20 ng/mL) 5(1.9%)
Insufﬁcient (20–31 ng/mL) 65(24.1%)
Sufﬁcient (> = 32 ng/mL) 200(74.1%)
Missing 76(NA)
TMEM16J Genotype (rs7111432)
AA 83(25.3%)
AG 180(54.9%)
GG 65(19.8%)
PKP3 Genotype (rs10902158)
AA 32(9.8%)
AG 153(46.6%)
GG 143(43.6%)
PKP3 Genotype (rs7105848)
CC 31(9%)
CT 140(43%)
TT 157(48%)
CYP2R1 Genotype (rs10741657)
AA 13(4.0%)
AG 100(30.5%)
GG 215(65.6%)
DHCR7 Genotype (rs12785878)
GG 218(66.5%)
GT 98(29.9%)
TT 12(3.7%)
VDBP Genotype (rs2282679)
AA 287(87.5%)
AC 39(11.9%)
CC 2(0.6%)
VDBP Genotype (rs4588)
AC 36(11.0%)
CC 292(89.0%)
VDBP Genotype (rs7041)
GG 3(0.9%)
GT 39(11.9%)
TT 286(87.2%)
VDR bsm Genotype (rs1544410)
AA 14(4.3%)
AG 115(35.1%)
GG 199(60.7%)
VDR fok-1 Genotype (rs10736810)
CC 227(69.2%)
CT 91(27.7%)
(Continued)
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(Fig 2A) For the outcome of any TB or death, the survival (K-M) curve for infants with low
vitamin D levels was significantly lower than those with normal vitamin D levels (unadjusted
risk difference 0.26, 95%CI 0.08–0.44; Fig 3A).
We assessed vitamin D as a continuous variable in models on all outcomes of interest, ignor-
ing the vitamin D polymorphisms, but found no significant result (data not shown).
Prevalence and association of SNPs with vitamin D levels, TB and death
The prevalence of allelic frequencies of SNPs assessed is shown in Table 2. None of the SNPs
evaluated were associated with an increased risk of low 25-hydroxyvitamin D (S2 Table). Addi-
tionally, no SNPs examined within the VDBP (rs2282679, rs4588, rs7041), VDR (rs10736810,
rs1544410, rs7975232, rs731236) or those reportedly associated with vitamin D levels
(rs12785878, rs10741657) significantly altered the risk for any TB or death (S3 Table). There
were, however, marginally significant associations between rs7041 and probable/definite TB or
death (aHR 3.25, 95%CI 0.95–11.1; p = 0.06; S3 Table).
In contrast to the findings relating to the vitamin D related SNPs, SNPs within the PKP3-SI-
GIRR-TMEM16J region significantly altered the risk for TB or death. In crude and adjusted
Cox models, having the TMEM16J (rs7111432) AA-allele was associated with approximately a
two-fold-increased risk of probable or definite TB (aHR 1.93, 95%CI 0.96–3.85; p = 0.06, mar-
ginally significant), any TB (aHR 1.75, 95%CI 0.91–3.37; p = 0.095, marginally significant) and
any TB or death (aHR 1.70, 95%CI 1.10–2.61; p = 0.016, significant). (Fig 2B) Similarly, having
the PKP3 (rs10902158) GG-allele was marginally associated with an increased risk of any TB
or death (aHR 1.44 95% CI 0.97–2.14; p = 0.07).(Fig 2C)
Low 25-hydroxyvitamin D status with SNPs in the
PKP3-SIGIRR-TMEM16J region genetic variants identify infants at high
risk for TB and death
We next examined whether infants with low 25-hydroxyvitamin D who also had specific SNPs
within the PKP3-SIGIRR-TMEM16J region would be at greater risk for TB or death. We
hypothesized that there would be an increased risk for TB or death because vitamin D has an
important role in innate immunity through autophagy induction [31, 32] and SNPs within the
PKP3-SIGIRR-TMEM16J region impair the down-regulation of toll-like receptor IL-1R signal-
ing, a pathway critical to host immune responses toMtb [15]. Consistent with our hypothesis,
there was a significant interaction between vitamin D status (low 25-hydroxyvitamin D or not)
and TMEM16J rs7111432 variants (GG genotype or not) in the adjusted models for any TB
(p = 0.04) and any TB or death (p = 0.04). There was also a significant interaction between vita-
min D status and PKP3 rs10902158 variants (AA genotype or not) in the adjusted models for
any TB or death (p = 0.02).
Table 2. (Continued)
Characteristic n(%**)
TT 10(3.1%)
*Vitamin D Insufﬁcient or Deﬁcient.
**Observed prevalence (excluded missing values in denominator).
***Missing genotype data for 18 subjects from sub-cohort of N = 346.
doi:10.1371/journal.pone.0148649.t002
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With combinations of vitamin D status and TMEM 16J rs7111432 variants as independent
variables in adjusted Cox proportional hazard models, we found that infants with low
25-hydroxyvitamin D and rs7111432-AA genotype had more than a 6-fold increased risk of
probable or definite TB (aHR = 6.54, 95%CI 1.07–39.83 p = 0.04, significant) and 8-fold
Table 3. Risk factors for low Vitamin D (25 hydroxyvitamin D) concentrations among the sub-cohort participants.
Characteristic Total (N = 270) Without low Vit D (N = 200) With low Vit D (N = 70) P-Value
Site 0.41**
Johannesburg 233 170(73%) 63(27%)
Cape Town 12 11(92%) 1(8%)
Durban 25 19(76%) 6(24%)
Infant characteristics
Mean age at draw date, months (s.d.) 7.59(1.93) 7.72(1.83) 7.21(2.18) 0.048*
Sex 0.05**
Male 128 102(80%) 26(20%)
Female 142 98(69%) 44(31%)
HIV Status 1.00**
HIV-infected 138 102(74%) 36(26%)
HIV-uninfected 132 98(74%) 34(26%)
Birth Weight<2500 gms 0.018**
Yes 49 43(88%) 6(12%)
No 221 157(71%) 64(29%)
Mean weight z-score (WHO) (s.d.) -0.90(1.47) -0.94(1.47) -0.80(1.49) 0.45*
Ever breastfed? 1.00**
Yes 31 23(74%) 8(26%)
No 239 177(74%) 62(26%)
Season of sample for Vitamin D
April-Sept 125 87(70%) 38(30%) 0.13**
Oct-March 145 113(78%) 32(22%)
Mother Ever had TB Diagnosis 0.25**
Yes 16 14(88%) 2(13%)
No 254 186(73%) 68(27%)
Household characteristics
>3 people sleep in room 0.68**
Yes 106 76(72%) 30(28%)
No 163 123(75%) 40(25%)
Not known 1 1(100%) 0(0%)
Any 55 year olds in house? 0.44**
Yes 78 55(71%) 23(29%)
No 192 145(76%) 47(24%)
Housing Type 0.004**
Formal (brick) house 190 131(69%) 59(31%)
Informal shack 80 69(86%) 11(14%)
Water access 0.07**
Running water in home 94 67(71%) 27(29%)
Running water on plot 134 96(72%) 38(28%)
Communal tap 42 37(88%) 5(12%)
*Wilcoxon test.
**Chi-square test.
doi:10.1371/journal.pone.0148649.t003
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Fig 2. Cox Proportional Hazard Models for TB disease or death, looking at (A) low vitamin D (LVD) status as risk factor ignoring genetic variant, (B)
TMEM16J rs7111432 variant as risk factor ignoring LVD status, and (C) PKP3 rs10902158 variant as risk factor ignoring LVD status.Model 1
adjusts for HIV infection status.Model 2 adjusts for HIV status, season, site, sex,weight z-score, type of house,mother prev TB diagnosis, age (in months) at
plasma draw date, and INH/Placebo group.Model 3 adjusts for HIV status, site, sex,weight z-score, type of house,mother prev TB diagnosis, and INH/
Placebo group. Evts/LVD = no. of events/no. of subjects with low vitamin D (%). Evts/NotLVD = no. of events/no. of subjects without low vitamin D (%). Evts/
AA = no. of events/no. of subjects with AA genotype (%). Evts/NotAA = no. of events/no. of subjects without AA genotype (%). Evts/GG = no. of events/no. of
subjects with GG genotype (%). Evts/NotGG = no. of events/no. of subjects without GG genotype (%).
doi:10.1371/journal.pone.0148649.g002
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increased risk of probable/definite TB or death (HR = 8.12 95% CI 1.85–35.67 p = 0.006, signif-
icant) compared to those without low vitamin D and without AA genotype. When including
possible TB events, the risk remained more than 4-fold increased (any TB HR = 4.19 95% CI
1.79–9.83 p = 0.001, significant; and any TB or death HR = 4.78 95% CI 2.06–11.09 p = 0.0003,
significant). (Fig 4A) Adjusting for multiple testing, and using a false discovery rate of
FDR = 0.05, the comparison of risk of any TB or death between subjects with combination of
LVD / rs7111432-AA genotype versus those with combination of not LVD / rs7111432-not
AA genotype remained significant. For any TB or death, the K-M plot shows a much lower sur-
vival curve among infants with low vitamin D levels and with the AA genotype compared to
the three more similar curves representing the other combinations (e.g., unadjusted risk differ-
ence versus infants with normal vitamin D level and with the AG/GG genotype is 0.34 with
95%CI 0.12–0.56; Fig 3B).
Fig 3. Kaplan-Meier Plots on Tuberculosis Free Survival (from all available data in case-cohort) by (A) Vitamin D status, (B) Vitamin D status /
rs7111432 variant and (C) Vitamin D status / rs10902158 variant.Risk differences were computed as the differences in Kaplan-Meier survival estimates
at end of follow-up period for this analysis, and were not adjusted for covariates.
doi:10.1371/journal.pone.0148649.g003
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Fig 4. Cox Proportional Hazard Models for TB disease or death, looking at (A) combination of low Vitamin D (LVD) status and TMEM 16J rs7111432
variant [AA genotype or not] as risk factor, and (B) combination of LVD status and PKP3 rs10902158 variant [GG genotype or not] as risk factor. A:
Model adjusts for HIV status, season, site, sex, weight z-score, type of house, mother with previous TB diagnosis, age (in months) at plasma draw date, and
INH/Placebo group. B: Model adjusts for HIV status, season, site, sex, weight z-score, type of house, mother with previous TB diagnosis, age (in months) at
plasma draw date, and INH/Placebo group.
doi:10.1371/journal.pone.0148649.g004
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Similarly, models fitted with a combination of vitamin D status and PKP3 rs10902158 vari-
ants as independent variables demonstrated that having low 25-hydroxyvitamin D and
rs10902158-GG genotype had a significantly higher risk of probable/definite TB or death
(aHR = 4.83, 95%CI 1.26–18.50; p = 0.02) as well as any TB (aHR 2.73, 95%CI 1.29–5.75;
p = 0.009) or any TB or death (3.26, 95%CI 1.54–6.93; p = 0.002). (Fig 4B) Adjusting for multi-
ple testing, and with an FDR = 0.10, the comparison of risk of any TB or death between subjects
with combination of LVD / rs10902158-GG genotype versus those with combination of not
LVD / rs10902158-not GG genotype remained significant. For the outcome of any TB or
death, the K-M plots are shown in Fig 3C shows the much lower survival curve among infants
with low vitamin D levels and with the rs10902158-GG genotype compared to the three more
similar curves representing the other combinations (e.g., unadjusted risk difference versus
infants with normal vitamin D level and with the AA/AG genotype is 0.56 with 95%CI 0.43–
0.68).
Discussion
This study has several key findings. First, 26% of young children residing in a high TB and HIV
burden setting had low levels of 25-hydroxyvitamin D. Second, low 25-hydroxyvitamin D
below 32 ng/mL was associated with a 1.7-fold increased risk for TB and death independent of
host variants. Third, we demonstrate that genetic variants within the PKP3-SIGIRR-TMEM16J
gene region (PKP3-rs10902158-A/G and TMEM16J- rs7111432 G/A) are significantly associ-
ated with a 40% to 70% increased risk for pediatric TB and death. Lastly, the most intriguing
and relevant finding was the interaction between low 25-hydroxyvitamin D and PKP3-SI-
GIRR-TMEM16J host variants. To our knowledge, we demonstrate for the first time that young
children with both low 25-hydroxyvitamin D and the rs7111432-AA have a 4- to 8-fold
increased risk of TB or death. Similarly, those with both low 25-hydroxyvitamin D and
rs10902158-GG genotypes have a 3- to 4-fold increased risk for developing TB or dying. It is
likely that such effect modifying variants will have important implications for vitamin D sup-
plementation strategies. Vitamin D supplementation may have greatest benefit in preventing
TB in children with both low levels of 25-hydroxyvitamin D and PKP3-SIGIRR-TMEM16J host
variants reported in our study.
We observed that 26% of infants were vitamin D insufficient or deficient. This prevalence is
lower than reported elsewhere [33]. In agreement with the infant feeding policy for HIV
exposed infants in South Africa at the time the study was conducted, a high proportion of the
children in our study were fed vitamin D fortified formula. As would be expected, few infants
were identified to be vitamin D deficient using the criterion of<20 ng/mL. For the purposes of
immunologic health, we apriori used a value of32 ng/mL 25-hydroxyvitamin D as sufficient.
In support of using a higher value of vitamin D for optimal immunologic health, Campbell and
Spector demonstrated that the activity of vitamin D3 againstMtb follows a dose response with
higher concentrations providing greater killing of the organism [34].
Low levels of vitamin D has long been implicated in the susceptibility to TB [35]. In our
study, children with low 25-hydroxyvitamin D had a 70% increased risk of developing any TB
or death. Molecular mechanisms responsible for the activity of vitamin D againstMtb are the
subject of considerable research [8]. For children who are infected withMtb but do not develop
disease, the infectious organisms can remain within the phagosomes of macrophages and may
not reactivate for decades [9].Mtb prevents the acidification of the phagosomes preventing the
maturation to phagolysosomes and the degradation of the mycobacteria. The trafficking path-
way whereby cytoplasmic constituents, including sub-cellular organelles, and microbial patho-
gens, such asMtb, are engulfed by phagosomes (or autophagosomes) which fuse with
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lysosomes forming phagolysosomes (or autolysosomes) leading to bulk degradation is termed
autophagy. Numerous studies have demonstrated that the induction of autophagy in vitro can
killMtb [31, 32]. In this regard, the active form of vitamin D (1,25D3) can induce autophagy
with the anti-mycobacterial activity dependent on the induction of autophagy and the expres-
sion of endogenous human cathelicidin microbial peptide [34].
Host genetic variations can alter both the risk for respiratory disease and severity of infec-
tion [9, 36]. Several studies have assessed the relationship between host genetic variants and TB
[37, 38]. The vast majority of these studies were conducted in adults, and association between
host genetic variants and risk of TB in pediatric populations remains unknown [8, 14]. A meta-
analysis of 23 studies showed an increased risk for TB associated with VDR polymorphisms
[12]. The Ff genotypes of FokI polymorphism were associated with increased risk and the bb
genotype of BsmI genotype with decreased risk of TB. Interestingly, this was only observed in
Asian populations. There does not appear to be an association between polymorphisms in
CYP27B1 which encodes 25-hydroxyvitamin D3 1-alpha-hydroxylase, an enzyme catalyzing
the hydroxylation of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D (the bioactive form of
vitamin D)[39]. Our study extends these findings to pediatric populations in high TB and HIV
burden settings. Children expressing the TMEM16J (rs7111432) AA-allele or the PKP3
(rs10902158) GG-allele had a nearly 2-fold increased risk of any TB or death. However, we did
not find a significant association between CYP27B1, rs7041, rs4588, Fok1 and Bsml SNPs and
risk of TB or death. We did however find a trend towards significance with VDBP rs7041 and
probable/definite TB or death, not found when adding possible TB to the outcome. The low
prevalence of the rs7041 GG/GT allele (43/346, 12.8%) may have contributed to the lack of
consistency in direction of results for this SNP, but the presence of some signals in this cohort
suggests the need for further study of this particular SNP in larger cohorts.
The modification of the association between host genetic variants and TB by vitamin D sta-
tus has been observed in a series of studies in adults. Increased TB risk in adults was associated
with the TT or Tt alleles of TaqI and the ff allele of FokI, but only in persons with vitamin D
deficiency [10]. However while Gc genotypes (which are encoded in the VDBP) are not gener-
ally associated with active TB, Martinueau and colleagues observed that the Gc2/2 genotype is
strongly associated with development of active TB compared with Gc1 but only in Gujurati
Indians and specifically in those with low vitamin D [21]. TLRs play an important role in path-
ogen recognition and triggering host innate immune responses [40]. Therefore, we hypothe-
sized that genetic variants within the PKP3-SIGIRR-TMEM16J gene region that affect TLR
expression recently identified to be associated with susceptibility to TB would exacerbate the
risk of TB in children with low vitamin D levels. Our findings support this supposition and
demonstrate a strong synergy between low vitamin D levels and specific SNPs within the
PKP3-SIGIRR-TMEM16J gene region, and the risk for TB and death among children. Young
children in our study with both low vitamin D levels and rs7111432-AA or rs10902158-GG
genotypes had a 3- to 8-fold increased risk of TB or death, an association much higher than
that observed for low vitamin D concentrations or PKP3-SIGIRR-TMEM16J SNPs alone. It is
therefore possible that children with SNPs in the PKP3-SIGIRR-TMEM16J gene region may
selectively benefit from anti-mycobacterial activity of vitamin-D and therefore may potentially
be prime targets for vitamin-D supplementation.
Our study has a few limitations. The majority of our children were formula fed which at the
time was the standard of care in South Africa for HIV-exposed children. Breastfed children
tend to have lower vitamin D concentrations than formula fed children as formula has some
vitamin D supplementation. Therefore, our prevalence of low vitamin D is likely an underesti-
mate since now the national policy has changed back to promoting exclusive breastfeeding.
Our study data were from a well-conducted clinical trial where TB and death were rigorously
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evaluated. However, we noted that many deaths were due to infectious etiologies other than TB
(diarrhea, respiratory, sepsis), and therefore our findings are consistent with the fact that the
host variants associated with innate immunity were indeed relevant to both TB and other infec-
tions. Another limitation to our study is that the genetic associations identified may not be due
to PKP3 or TMEM16J SNPs. As noted by Horne et al.,[15] the SNPs identified as important in
PKP3 or TMEMJ16may be in linkage disequilibrium with SNPs within SIGIRR. The SIGIRR
(also known as TIR8) region is a biologically important modulator of TLR-IL-1R signaling,
inhibits NF-kappa B, modulates inflammation and in the mouse model has been shown to reg-
ulate harmful responses to infections such as TB [16]. The PKP3/TMEM16J flank the SIGIRR
but have unknown functions. Thus it is possible that other SNPs within the SIGIRR region are
responsible for the direct effects on microbial pathogenesis or that PKP3/TMEM16J regions
have as yet an unidentified role in innate immunity. Finally, the study participants in this anal-
ysis were not fully representative of the parent P1041 study population due to differences in eli-
gibility for analysis with respect to certain participant characteristics and sample availability.
However, these differences are unlikely to change our overall interpretation of the associations
we detected.
The World Health Organization and United Nations Millennium Development Goals call
for dramatic reductions in pediatric TB cases and childhood mortality, respectively. Identifying
children at high risk for TB or death therefore is a global priority. We found an association of
vitamin D levels with the risk for development of TB or death in HIV-infected and –exposed
but uninfected infants in South Africa. Additionally, specific variants within the PKP3-SI-
GIRR-TMEM16J gene region were also associated with risk of TB or death. More importantly,
genetic variants combined with low vitamin D status identified infants at highest risk for TB
disease or death. These findings suggest that vitamin D supplementation of infants may be of
benefit to infants in high TB burden countries, and that children with specific genetic varia-
tions may benefit from supplementation to a greater extent. Clinical trials are needed to evalu-
ate the benefits of supplemental vitamin D in high-risk settings.
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